Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad)tc pixel

Demant A/S (OTCMKTS:WILYY) Stock Price Down 4.2% - What's Next?

Written by MarketBeat
Updated August 17, 2025
Demant A/S logo with Medical background

Key Points

  • Demant A/S shares fell 4.2% on Tuesday, trading at $19.27, with a significant increase in trading volume (259%) compared to its average.
  • Barclays recently upgraded Demant A/S from a "strong sell" to a "hold" rating, while Citigroup boosted its rating from "hold" to "strong buy," contributing to a current consensus rating of "Buy."
  • The company specializes in hearing healthcare and audio technology, and operates across multiple international markets including Europe and North America.
  • Five stocks we like better than Demant A/S.

Demant A/S Unsponsored ADR (OTCMKTS:WILYY - Get Free Report)'s share price was down 4.2% during mid-day trading on Tuesday . The stock traded as low as $19.27 and last traded at $19.27. Approximately 101 shares changed hands during mid-day trading, an increase of 259% from the average daily volume of 28 shares. The stock had previously closed at $20.11.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on WILYY shares. Citigroup upgraded Demant A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Barclays upgraded Demant A/S from a "strong sell" rating to a "hold" rating in a report on Friday, June 20th. Two research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy".

Check Out Our Latest Stock Analysis on WILYY

Demant A/S Stock Performance

The stock's fifty day simple moving average is $20.58 and its two-hundred day simple moving average is $18.88. The company has a quick ratio of 1.22, a current ratio of 1.63 and a debt-to-equity ratio of 1.29.

Demant A/S Company Profile

(Get Free Report)

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services.

Featured Stories

Should You Invest $1,000 in Demant A/S Right Now?

Before you consider Demant A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Demant A/S wasn't on the list.

While Demant A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.